Indian envoy meets Yemen leaders, discusses bilateral ties
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Value Chain
29 minutes ago
- Fashion Value Chain
Solo-Dex and Polymedicure Partner to Bring Opioid-Free Acute Pain Management to India and Major Asian Markets
Solo-Dex, Inc., a U.S.-based medical device innovator, and Polymedicure Ltd. (Polymed), Indias leading manufacturer of high-quality medical devices, today announced a strategic manufacturing and supply partnership to bring Solo-Dexs patented, opioid-free regional anesthesia solutions to hospitals across India for the first time. Under this agreement, Polymed will manufacture Solo-Dexs flagship product, the Fascile Continuous Peripheral Nerve Block system, in accordance with Solo-Dexs strict quality standards, for distribution across India and key global markets. The product is already approved for clinical use in the United States and Europe and is now set to support Indias expanding Enhanced Recovery After Surgery (ERAS) programs and the growth of outpatient surgical care. 'This is a game-changer for pain management in India,' said Steven Eror, CEO of Solo-Dex. 'Polymeds scale, precision, and strong regulatory framework make them the ideal manufacturing partner. Together, well deliver a transformative technology that goes far beyond suppressing pain-it blocks acute pain completely.' First-of-its-kind in India: Faster, Safer, Non-Opioid Pain Control Solo-Dexs patented device installs in under two minutes and enables continuous, localized pain relief without opioids. Unlike conventional methods that may require IV sedation and can result in patient delirium, Solo-Dex minimizes systemic drug exposure, and eliminates the need for oral opioids thereby improving patient safety, reducing recovery time, and decreasing demand on hospital resources. The technology is designed to seamlessly integrate with ERAS protocols, helping hospitals manage post-operative pain more efficiently. As Indias healthcare system increasingly embraces day surgery and outpatient models, Solo-Dex offers a solution that enhances patient throughput and satisfaction without compromising clinical outcomes. 'We are excited to be part of this international collaboration,' said Himanshu Baid, Managing Director of Polymed. 'This partnership not only brings cutting-edge pain management to Indian clinicians and patients, but also aligns with our commitment to making world-class healthcare more accessible.' Designed for Global Impact Manufacturing will take place in Polymeds ISO 13485-certified, FDA-auditable facilities, with initial orders for 100,000 units. In addition to serving India, the partnership aims to fulfill international demand across Asia, Africa, Latin America, and select European markets, with Solo-Dex overseeing global regulatory compliance and branding. 'Thanks to this agreement, Solo-Dex now has the scalable, cost-effective production capacity to meet global demand while maintaining the clinical precision and quality our technology requires,' said Eror. 'Were especially proud to collaborate with Polymed to address the worldwide need for safer, opioid-free surgical recovery.' The Solo-Dex and Polymed partnership is already engaging with leading hospital systems across India, with commercial availability expected to begin in Q4 2025. About Solo-Dex, Inc. Solo-Dex is a U.S.-based medical device company focused on opioid-free acute pain management. Its patented continuous peripheral nerve block systems enable anesthesiologists to deliver localized, long-lasting anesthesia for post-surgical recovery. Solo-Dex technology is approved for clinical use in the U.S. and EU. About Polymedicure Limited Polymed is one of Indias most trusted names in medical devices, with a portfolio of more than 125 FDA-approved and CE-marked products. With a global presence in over 100 countries, Polymed operates high-end manufacturing facilities and is committed to delivering innovative, high-quality healthcare solutions at scale.
Economic Times
29 minutes ago
- Economic Times
Zelensky says "we will not leave Donbass" and rules out land swap with Russia
Synopsis President Zelensky has firmly rejected any voluntary troop withdrawal from Ukrainian-controlled Donbass territories, dismissing land swap proposals with Russia. He emphasized that ceding land would only enable future Russian aggression. Zelensky's stance contrasts with Trump's suggestion of territorial concessions for a peace deal. ANI Zelensky says "we will not leave Donbass" and rules out land swap with Russia Ukrainian President Vladimir Zelensky has ruled out any voluntary withdrawal of Ukrainian troops from territories still under Kyiv's control in Donbass, dismissing suggestions they could be part of a potential land swap with Russia, RT to reporters on Tuesday, Zelensky said, "We will not leave Donbass. We cannot do this. Everyone forgets the main issue, our territories are illegally occupied," adding that ceding land in Donbass to Russia would only allow it to start a new war in a couple of years and push deeper into Ukraine, RT reported."Any issue of territories cannot be separated from security guarantees. Otherwise, now they want to gift them about 9,000 square kilometers; this is about 30% of the Donetsk region, and this is a springboard for their new aggression," he claimed, according to RT. The remarks follow repeated comments by US President Donald Trump that a potential peace deal between Moscow and Kyiv would likely involve a land swap and territorial concessions from both sides. "They've [Russia] occupied some very prime territory. We're going to try and get some of that territory back for Ukraine," Trump said on Monday, as cited by RT. The Lugansk (LPR) and Donetsk (DPR) People's Republics, along with the Zaporozhye and Kherson regions, became part of Russia after referendums in 2022. While the LPR was fully taken by Russian forces earlier this year, Moscow's control over the other regions remains partial. Kyiv continues to claim all four territories, as well as Crimea, which joined Russia in 2014 following a referendum held shortly after the Western-backed Maidan coup in Kyiv, RT reported. Zelensky has repeatedly rejected any territorial concessions to Russia, while Moscow insists any peace deal must involve Ukraine's withdrawal from the country's newly incorporated regions, according to RT. The remarks highlight the continuing deadlock between Ukraine and Russia over territorial control.
Economic Times
29 minutes ago
- Economic Times
Waaree, Premier Energies shares tumble up to 4% after US launches solar cell dumping probe
Shares of Waaree Energies Ltd and Premier Energies Ltd tumbled up to 4% on Wednesday, August 13, following a significant regulatory move by the US Department of Commerce. ADVERTISEMENT Shares of Waaree Energies fell by 3.9% to their day's low of Rs 2,963.50 on the BSE, while Premier Energies shares slid by 1.6% to Rs 998.90. According to a report by CNBC TV-18, the department has launched antidumping and countervailing duty investigations into crystalline silicon photovoltaic cells, whether assembled into modules or not, originating from India, Indonesia, and Laos. These probes aim to determine whether these countries have been exporting solar cells to the US at unfairly low prices or with government to the Commerce Department's findings so far, Indian solar cells are being shipped to the US at a dumping margin of 123%, with an additional subsidy rate of 2%.This development could have notable implications for Indian exporters to the US. The department is expected to release its preliminary conclusions on the matter by September 2, which could set the stage for potential tariffs or other trade measures. ADVERTISEMENT For Waaree Energies, the timing of the probe is particularly critical. As of the June quarter, the company had an order book of 25 GW worth Rs 49,000 crore, with exports accounting for a substantial 41.3% of the total. Any adverse ruling from the US could impact a considerable portion of its international business. Unlock 500+ Stock Recos on App On the other hand, Premier Energies appears less vulnerable to the development, as the company's focus remains largely on the domestic market, with minimal exposure to the US. ADVERTISEMENT On Tuesday, the shares of Waree Energies closed 0.9% lower at Rs 3,084.30 on the BSE, while those of Premier Energies closed 1.2% higher at Rs 1,015.55. Also read: Reliance AGM may offer Jio IPO timeline, retail outlook: Neeraj Dewan (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
